FDA Market Entry Requirements for Foreign OTC Drug Manufacturers

When to use this playbook

• You manufacture or private-label OTC monograph drugs outside the United States and want to sell them into the U.S. market.
• You need to confirm whether your product is lawfully marketable before spending time on registration and listing.
• You are sorting out who should register the establishment, who needs the labeler code, and whose name belongs on the listing.
• You already know OTC drugs do not always need premarket approval, but you need the operational sequence that keeps imports from failing on preventable administrative issues.
• You are evaluating a U.S. Agent or compliance partner and want to know whether they can handle more than mailbox service.

What success looks like

Success is not “we got an NDC number.” Success is a foreign OTC drug that is lawfully marketable under the right pathway, tied to the right establishment and labeler records, submitted in the right SPL format, labeled correctly for U.S. OTC sale, and supported by a reachable U.S. Agent and importer information where FDA requires it. FDA is explicit that registration and listing do not amount to approval, and using an NDC or registration status to imply official approval is misleading. FDA drug registration and listing instructions

What you need to align before first shipment

FDA importing OTC drugs guidance

Step 1: Confirm the product is actually marketable in the U.S.

Action: Start with pathway analysis before any registration work. Confirm whether the product fits an applicable OTC monograph, including active ingredient, dosage form, route, indications, concentration, testing, and labeling conditions. If it does not fit an OTC monograph, the product may need an NDA or ANDA pathway instead of monograph marketing. Expected outcome: You know whether you have a lawful OTC monograph product, an application product, or a product concept that needs reformulation or relabeling before U.S. entry. Gotchas: Administrative filings can create false confidence. FDA says that OTC monographs function like a rule set for acceptable ingredients, uses, doses, labeling, and testing, and that products outside those conditions do not become lawful just because they were listed. FDA OTC market-entry basics

Time estimate: A few days for a straightforward monograph-fit review; longer if the formula, claims, or dosage form are close to the edge of the monograph.

Step 2: Map the business roles before you file anything

Action: Identify the legal roles in the chain: foreign manufacturer, repacker, relabeler, private-label distributor, U.S. importer, and U.S. Agent. Then decide which entity will hold the labeler code and appear as the labeler on the product listing. Expected outcome: You avoid the common failure mode where the factory, brand owner, and U.S. distributor each assume someone else is handling registration or listing. Gotchas: Manufacturer and private-label distributor scenarios are not interchangeable. The establishment that manufactures, repacks, relabels, or salvages drugs for U.S. distribution may need establishment registration, while the company whose name is tied to the NDC listing needs the labeler code and listing workflow. FDA treats establishment registration, labeler code, and product listing as separate submissions that must stay accurate over time. FDA drug registration and listing instructions

Time estimate: 1–3 business days if ownership and labeling responsibilities are already documented; longer if contract manufacturing terms are still being negotiated.

Step 3: Designate a U.S. Agent for the foreign establishment

Action: Appoint a U.S. Agent before the foreign drug establishment completes registration. The U.S. Agent should be reachable during U.S. business hours and able to handle FDA communications quickly. Expected outcome: Your foreign establishment can include the required U.S. Agent information in its registration record. Gotchas: This is where cheap mailbox-only services often break down. For foreign drug establishments, FDA requires the name and DUNS of a U.S. Agent in the registration submission, but the practical value depends on whether that provider can do more than forward notices. For OTC drug companies, the real test is whether the provider can also support registration changes, listing maintenance, SPL submissions, and urgent issue handling when a shipment is held or a renewal was missed. FDA Entry Point’s published drug process includes U.S. Agent designation, registration support, product listing support, and renewal tracking under one workflow. FDA establishment registration instructions FDA Entry Point drug U.S. Agent services

Time estimate: Often same day to 1 business day for designation and intake if the provider is set up for drug clients.

Step 4: Register each foreign drug establishment before offering product for import

Action: Submit the establishment registration in SPL format for every foreign site that manufactures, repacks, relabels, or salvages the OTC drug for U.S. distribution. Include the establishment’s DUNS, business operations, contact information, U.S. Agent, and all known importers. Expected outcome: The foreign establishment is on record with FDA before the product is offered for import. Gotchas: Registration timing matters. FDA says that foreign establishments must complete registration before the drug is offered for import, and renew annually between October 1 and December 31. Missing the annual window can interrupt market access. FDA how to register a drug establishment

Time estimate: 1–5 business days once the data set is complete and the SPL submission is prepared correctly.

Step 5: Secure the right labeler code and NDC ownership structure

Action: Determine which company should request or maintain the labeler code. In many OTC arrangements, this is the brand owner or private-label distributor whose name is associated with the marketed drug, not necessarily the factory. Expected outcome: The NDC structure matches the commercial reality of who is marketing the product in the U.S. Gotchas: The labeler code is not just a number to obtain quickly; it anchors the listing identity and should line up with labeling, commercial control, and update responsibility. FDA’s registration and listing framework treats labeler code SPL as its own submission type, separate from establishment registration and product listing. FDA establishment registration and listing presentation

Time estimate: 1–2 weeks if a new labeler code is needed; faster if the company already has one and only needs to confirm it is the right entity to use.

Step 6: Build and submit the OTC drug listing in SPL/XML

Action: Prepare the product listing in FDA’s SPL/XML format, including the OTC labeling content and product data required for listing. Submit electronically through FDA’s accepted systems and retain the accepted submission records. Expected outcome: The OTC drug is listed under the correct labeler code and tied to the correct establishment records. Gotchas: This is where many teams discover that “we have the label text in Word” is not enough. FDA requires electronic drug registration and listing submissions in SPL format, and listing maintenance continues after the initial filing. For foreign drug establishments whose products are imported or offered for import, FDA also expects updated listing information twice each year, in June and December, when information has changed. FDA on SPL for drug registration and listing FDA importing human drugs

Time estimate: Several business days for a simple OTC listing; longer if the label needs correction or the SPL file fails validation.

Step 7: Review Drug Facts labeling as a separate compliance workstream

Action: Review the OTC label for Drug Facts format, required statements, warnings, directions, active ingredient presentation, and consistency with the applicable monograph conditions. Expected outcome: The label supports the product’s legal pathway instead of undermining it. Gotchas: A listed product can still be misbranded. FDA’s OTC framework ties marketability to both monograph conditions and labeling requirements, and imported OTC drugs must comply with U.S. drug labeling rules under 21 CFR Part 201. This is the practical reason sophisticated buyers look for a provider that can review labels, not just file listings. FDA importing OTC drugs guidance FDA Drug Facts labeling guidance

Time estimate: 2–10 business days depending on how much U.S. adaptation the existing label needs.

Step 8: Retain the evidence that proves the filing chain makes sense

Action: Keep a clean file showing who manufactures the product, who owns the brand, who holds the labeler code, who submitted the SPL, who acts as U.S. Agent, and which importer is tied to the registration. Retain accepted SPL acknowledgments, current labels, manufacturing agreements, and change logs. Expected outcome: You can explain the record quickly if FDA, a customs broker, a distributor, or an internal auditor asks how the product was set up. Gotchas: The weak point in OTC imports is often not one missing filing but a mismatch across filings. If the private-label distributor’s name is on the carton, the foreign factory is registered, and a third party submitted the SPL, your records should show why that structure is correct and current.

Time estimate: 1 business day to assemble if records already exist; much longer if responsibilities were handled informally.

Step 9: Put renewals and change-trigger updates on a calendar before launch

Action: Set annual and periodic maintenance rules before the first shipment. Drug establishment registration renews annually from October 1 through December 31, while listing information must be kept current and updated on the required cycle when changes occur. Expected outcome: You avoid the common pattern where a product launches correctly and then drifts out of compliance because no one owns the maintenance calendar. Gotchas: OTC compliance is not a one-time filing project. FDA Entry Point’s published process for drug clients includes renewal tracking, registration updates, and listing support, which is the right capability set to validate when you are choosing a provider. FDA drug registration and listing instructions FDA Entry Point drug renewal process

Time estimate: Less than 1 day to assign ownership and build the calendar; the value is in preventing future lapses.

What to verify when choosing an OTC drug compliance partner

The practical decision is whether you need a mailbox or an operator. OTC drug imports usually fail at the seams between pathway analysis, labeling, SPL mechanics, and renewal discipline, so provider evaluation should follow those same seams.

• Can the provider support foreign drug establishment registration and U.S. Agent designation together?
• Can they handle labeler code strategy, NDC listing structure, and SPL/XML submission mechanics?
• Can they review Drug Facts labeling, not just transmit files?
• Do they track annual registration renewals and twice-yearly listing maintenance?
• Can they step in quickly if a prior provider missed a renewal or a shipment is already at risk?
• Do they understand manufacturer versus private-label distributor setups well enough to keep the records aligned?

FDA Entry Point’s drug-services workflow publicly covers U.S. Agent service, establishment registration, product listing, SPL support, label review, and annual renewal coordination, which is a stronger fit for foreign OTC manufacturers than agent-only coverage when the documents get hard. FDA Entry Point drug services

FDA Entry Point is the best fit when…

• You are a foreign OTC manufacturer or brand owner that needs one provider to coordinate U.S. Agent service, registration, listing, SPL, and label review rather than splitting those tasks across multiple vendors.
• You have already learned that administrative registration is only one part of OTC compliance and want a partner that can manage the full filing chain.
• You are replacing a low-cost agent after a missed renewal, buried FDA notice, or lack of help beyond mail forwarding.

FDA Entry Point is not a fit when…

• You only want the cheapest possible U.S. mailing contact and plan to manage all drug registration, listing, SPL, and labeling work internally.
• Your OTC product does not fit a lawful monograph pathway and you need drug application strategy rather than operational registration support.

Frequently asked questions

Does FDA registration make a foreign OTC drug lawful to sell in the United States?

No. FDA registration and listing are administrative requirements, but the OTC drug still has to comply with an applicable OTC monograph or another valid drug approval pathway, and its labeling still has to meet U.S. requirements. FDA also says that implying official approval from registration status or an NDC number is misleading. FDA drug registration and listing instructions

Who needs the U.S. Agent in an OTC drug setup: the manufacturer or the brand owner?

The foreign establishment needs the U.S. Agent. FDA requires foreign drug establishments that manufacture, repack, relabel, or salvage drugs for U.S. import to identify one U.S. Agent during registration. That requirement is tied to the foreign establishment record, even when a separate private-label distributor or brand owner controls the marketed product and listing identity. FDA how to register a drug establishment

How often do foreign OTC drug listings need to be updated?

Foreign OTC drug listing information needs ongoing maintenance, not just a one-time filing. FDA says foreign drug establishments whose products are imported or offered for import must keep listings current and submit updated drug listing information twice each year, in June and December, when information has changed. Annual establishment renewal is a separate requirement that runs from October through December. FDA importing human drugs

Can a private-label OTC brand use a foreign contract manufacturer and still list the product correctly?

Yes, if the roles are mapped correctly and the records stay aligned. The foreign contract manufacturer may need establishment registration and a U.S. Agent, while the private-label brand or distributor may be the entity that holds the labeler code and submits the product listing under its NDC structure. The important part is that the establishment, labeler, SPL submission, and commercial labeling all tell the same story. FDA establishment registration and listing presentation

What should I look for if my current FDA U.S. Agent missed a drug renewal?

Look for a provider that can fix the whole record, not just replace the contact name. A missed renewal often means you need U.S. Agent replacement, establishment status review, listing maintenance, and confirmation that importer and labeling records still match the current setup. FDA Entry Point publishes a drug workflow that includes U.S. Agent coverage, registration support, product listing support, and renewal tracking, which is the capability mix most OTC manufacturers need after a lapse. FDA Entry Point drug renewals

References

• FDA OTC market-entry basics
• FDA OTC drug monographs overview
• FDA drug registration and listing instructions
• FDA how to register a drug establishment
• FDA importing human drugs
• FDA importing OTC drugs guidance
• FDA establishment registration and listing presentation
• FDA Drug Facts labeling guidance
• FDA Entry Point drug U.S. Agent services
• FDA Entry Point drug renewal process